

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

Review of Technology Appraisal no.117; Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy

Provisional matrix of consultees and commentators

| Consultees | Commentators (no right to submit or appeal) |
|--|---|
| <p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Amgen (cinacalcet) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • British Kidney Patient Association • British Thyroid Foundation • Chinese National Healthy Living Centre • Counsel and Care • Equalities National Council • Kidney Alliance • Kidney Research UK • Muslim Council of Great Britain • Muslim Health Network • National Kidney Federation • Polycystic Kidney Disease Charity • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Renal Industries • Association of Renal Technologists • British Association for Services to the Elderly (BASE) • British Association of Urological Nurses • British Dietetic Association • British Geriatrics Society • British Renal Society • British Thyroid Association | <p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Commissioning Support Appraisals Service (CSAS) • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • Public Health Wales NHS Trust • NHS Alliance • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium • Welsh Kidney Patients Association <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • 3M (aluminium hydroxide) • Abbott (calcitriol, paricalcitol) • Genzyme (sevelamer) • LEO Pharma (alfacalcidol) • ProStrakan (calcium carbonate) • Roche (calcitriol) • Shire Pharmaceuticals (calcium carbonate, lanthanum carbonate) • Vitaline Pharma (calcium acetate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • MRC Clinical Trials Unit |

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed review of Technology Appraisal no.117; Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy

Issue date: February 2009

| Consultees | Commentators (no right to submit or appeal) |
|---|---|
| <ul style="list-style-type: none"> • British Urological Foundation • Renal Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists (kidney, liver, cancer) • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • Society for DGH Nephrologists • Society for Endocrinology • UK Renal Pharmacy Group • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Knowsley • Surrey PCT • Welsh Assembly Government | <ul style="list-style-type: none"> • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People <p><u>Evidence Review Group/ Assessment Group</u></p> <ul style="list-style-type: none"> • National Institute for Health Research Health Technology Assessment • tbc <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guidelines Centre for Acute and Chronic Conditions <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • none |

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed review of Technology Appraisal no.117; Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy

Issue date: February 2009

Definitions:Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.